Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Allmed Medical Products Co., Ltd specializes in the production of medical instruments and supplies, with a strong presence in the Chinese healthcare market. The company differentiates itself through its focus on high-quality disposable medical products and innovative solutions that cater to hospitals and clinics across China.
Allmed generates revenue primarily through the sale of disposable medical supplies and surgical instruments, leveraging its established distribution network across hospitals in China. The company benefits from strong pricing power due to its reputation for quality and reliability, which is critical in the healthcare sector.
Changes in healthcare regulations affecting medical supply procurement
Fluctuations in demand for disposable medical products due to public health trends
Competitive pricing strategies from domestic and international rivals
Expansion of hospital networks and healthcare infrastructure in China
Regulatory changes in medical device approvals and standards
Technological disruption from new medical technologies
Intensifying competition from both domestic and international medical supply companies
Potential price wars that could erode margins
Low liquidity risk due to a healthy current ratio of 1.85
Potential risks from fluctuating raw material costs impacting production expenses
moderate - The demand for medical supplies is somewhat insulated from economic cycles, but significant downturns can affect hospital budgets and procurement.
Interest rates impact financing costs for expansion and R&D investments, which can affect profitability and growth potential.
minimal - The company has a low debt-to-equity ratio, indicating limited reliance on external financing.
growth - Investors are likely attracted by the company's potential for expansion in the growing Chinese healthcare market.
moderate - The stock has shown some volatility, particularly with a recent 3-month return of -13.8%.
